Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARZAN
2024-517119-59-00Phase 2Authorised
- Sponsor
- Netherlands Cancer Institute
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab and bevacizumab in rectal cancer, sponsored by Netherlands Cancer Institute. Primary endpoint: Clinical complete and near-complete response rate at week 12 post-radiotherapy. Planned start Oct 2024; status: authorised.
02
Drugs
atezolizumabbevacizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2024-517119-59-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517119-59-00.